In addition, GLP-1/glucagon (GCG) receptor dual agonists or GLP-1/GCG/GIP receptor triple agonists are attractive NAFLD/NASH therapeutics, due to improved effects on diet-induced metabolic deterioration and steatohepatitis in mice [58,59,60,61]. This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.